TrialThe Lancet. Respiratory medicine2015

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.

Richard B Moss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.